Related Experiment Video
Updated: Jul 2, 2026
Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia
Published on: January 23, 2009
Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia?
Michael P Murphy1, Hao Wang, Amit N Patel
1Division of Vascular Surgery, Indiana University School of Medicine, Indiana, USA. mipmurph@iupui.edu
Insights
Endometrial Regenerative Cells (ERCs) show promise for treating critical limb ischemia (CLI). These allogeneic cells offer an "off-the-shelf" alternative to autologous stem cells, potentially overcoming limitations in current regenerative medicine approaches for CLI.
Area of Science:
- Regenerative Medicine
- Vascular Biology
- Stem Cell Therapy
Background:
- Critical limb ischemia (CLI) is a severe peripheral artery disease complication, leading to numerous amputations annually.
- Current autologous stem cell therapies for CLI face challenges including reduced cell efficacy in older patients, invasive procedures, and the need for on-site cell processing.
Purpose of the Study:
- To explore the potential of allogeneic Endometrial Regenerative Cells (ERCs) as an alternative treatment for CLI.
- To highlight the advantages of ERCs over existing autologous cell therapies for CLI.
Main Methods:
- Review of the properties of Endometrial Regenerative Cells (ERCs).
- Analysis of ERCs' potential for stimulating angiogenesis and their therapeutic benefits in preclinical models of CLI.
Main Results:
- ERCs exhibit high production of growth factors and matrix metalloproteinases, crucial for tissue repair and angiogenesis.
- ERCs demonstrate anti-inflammatory properties and low immunogenicity, suggesting suitability for allogeneic transplantation.
- ERCs can be expanded extensively without compromising their differentiation capacity or chromosomal stability.
Conclusions:
- Allogeneic ERCs represent a promising "off-the-shelf" therapeutic option for critical limb ischemia.
- ERCs may overcome the limitations associated with autologous stem cell treatments for CLI, offering a more practical and potentially more effective solution.
Abstract:
Critical limb ischemia (CLI) is an advanced form of peripheral artery disease which is responsible for approximately 100,000 amputations per year in the US. Trials to date have reported clinical improvement and reduced need for amputation in CLI patients receiving autologous bone marrow or mobilized peripheral blood stem cells for stimulation of angiogenesis. While such treatments are currently entering Phase III trials, practical and scientific pitfalls will limit widespread implementation if efficacy is proven. Hurdles to be overcome include: a) reduced angiogenic potential of autologous cells in aged patients with cardiovascular risk factors; b) invasiveness/adverse effects of bone marrow extraction and G-CSF mobilization, respectively; and c) need for on-site cellular manipulation. The Endometrial Regenerative Cell (ERC) is a mesenchymal-like stem cell derived from the menstrual blood that is believed to be associated with endometrial angiogenesis. We discuss the possibility of using allogeneic ERCs as an "off the shelf" treatment for CLI based on the following properties: a) High levels of growth factors and matrix metalloprotease production; b) Ability to inhibits inflammatory responses and lack of immunogenicity; and c) Expandability to great quantities without loss of differentiation ability or karyotypic abnormalities.
More Related Videos
07:50Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
01:19Clinical Applications of Epidermal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...